Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.

Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH, Lin YW.

J Pharmacol Exp Ther. 2011 Jul;338(1):184-94. doi: 10.1124/jpet.111.179663. Epub 2011 Mar 28.

2.

Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.

Weng SH, Tseng SC, Huang YC, Chen HJ, Lin YW.

Biochem Pharmacol. 2012 Jul 1;84(1):126-36. doi: 10.1016/j.bcp.2012.03.011. Epub 2012 Mar 27.

PMID:
22480737
3.

Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.

Ko JC, Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.

Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.

PMID:
21810436
4.

Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.

Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.

Lung Cancer. 2010 Aug;69(2):155-64. doi: 10.1016/j.lungcan.2009.10.013. Epub 2009 Dec 4.

PMID:
19962780
5.

Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.

Su YJ, Tsai MS, Kuo YH, Chiu YF, Cheng CM, Lin ST, Lin YW.

Mol Pharmacol. 2010 Apr;77(4):633-43. doi: 10.1124/mol.109.061887. Epub 2009 Dec 30.

6.

Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).

Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.

Mol Pharmacol. 2011 Jul;80(1):136-46. doi: 10.1124/mol.111.071316. Epub 2011 Apr 14.

7.

Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.

Biochem Pharmacol. 2011 Mar 1;81(5):680-90. doi: 10.1016/j.bcp.2010.12.008. Epub 2010 Dec 17.

PMID:
21168393
8.

Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.

Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, Lin ST, Chang CC, Lin YW.

Mol Cancer Res. 2009 Aug;7(8):1378-89. doi: 10.1158/1541-7786.MCR-09-0051. Epub 2009 Aug 11.

9.

Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.

Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A.

Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10.

10.

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.

Ko JC, Ciou SC, Cheng CM, Wang LH, Hong JH, Jheng MY, Ling ST, Lin YW.

Carcinogenesis. 2008 Jul;29(7):1448-58. doi: 10.1093/carcin/bgn130. Epub 2008 Jun 9.

PMID:
18544565
11.

Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.

Ko JC, Chiu HC, Syu JJ, Jian YJ, Chen CY, Jian YT, Huang YJ, Wo TY, Lin YW.

Biochem Pharmacol. 2014 Mar 1;88(1):119-27. doi: 10.1016/j.bcp.2014.01.010. Epub 2014 Jan 18.

PMID:
24447935
12.

Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.

Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Hölscher AH, Danenberg PV, Brabender J.

Clin Lung Cancer. 2010 Sep 1;11(5):328-34. doi: 10.3816/CLC.2010.n.041.

PMID:
20837458
13.

Enhancement of mitomycin C-induced cytotoxicity by curcumin results from down-regulation of MKK1/2-ERK1/2-mediated thymidine phosphorylase expression.

Weng SH, Tsai MS, Chiu YF, Kuo YH, Chen HJ, Lin YW.

Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):298-306. doi: 10.1111/j.1742-7843.2011.00806.x. Epub 2011 Nov 4.

14.

Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.

Liao KS, Wei CL, Chen JC, Zheng HY, Chen WC, Wu CH, Wang TJ, Peng YS, Chang PY, Lin YW.

Regul Toxicol Pharmacol. 2016 Nov;81:353-361. doi: 10.1016/j.yrtph.2016.09.031. Epub 2016 Sep 28.

PMID:
27693704
15.

The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.

Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R.

Lung Cancer. 2005 Sep;49(3):345-51.

PMID:
15993511
16.

MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.

Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R.

Oncogene. 2006 Jun 1;25(23):3335-45. Epub 2006 Feb 6.

PMID:
16462770
17.

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.

J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3.

19.

Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.

Ko JC, Hong JH, Wang LH, Cheng CM, Ciou SC, Lin ST, Jheng MY, Lin YW.

Mol Cancer Ther. 2008 Nov;7(11):3632-41. doi: 10.1158/1535-7163.MCT-08-0578.

20.

Supplemental Content

Support Center